HSHideya Sakakibara

Hideya Sakakibara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hideya Sakakibara has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Fumiki Hirahara

    Department of Obstetrics and Gynecology, Yokohama City University, Yokohama City, Japan

    2 shared publications
  • Hiromi Yoshikata

    Department of Gynecology, Yokohama City University Medical Center, Yokohama, Japan

    2 shared publications
  • Taku Tsuburai

    Department of Gynecology, Yokohama City University Medical Center, Yokohama, Japan

    2 shared publications
  • Tomomi Nakamura

    Department of Obstetrics and Gynecology, Yokohama City University School of Medicine, Yokohama, Japan

    2 shared publications
  • Akifumi Ijuin

    Department of Obstetrics and Gynecology, Yokohama City University Hospital, 3-9, Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

    1 shared publication
  • Akifumi Ijuin

    Center for Reproductive Medicine Yokohama City University Medical Center Yokohama Japan

    1 shared publication

Latest Publications

  • Effects of age at estrogen replacement therapy initiation on trabecular bone score in Japanese adults with Turner syndrome

    by S. Saito, E. Koga, Y. Okada, T. Tsuburai, H. Yoshikata, E. Miyagi, H. Sakakibara

    Summary The effects of the age at estrogen replacement therapy (ERT) initiation on bone quality in Turner syndrome were evaluated using trabecular bone score. Early puberty ERT positively correlated with increase in bone quality. Early initiation of ERT is necessary for the acquisition of bone quality as well as bone density. Introduction Studies have reported associations between bone mineral density and estrogen replacement therapy (ERT) in Turner syndrome (TS) patients; however, few studies exist on the effect on bone quality. The aim of this study was to evaluate the effects of the age at ERT initiation on bone quality of Japanese TS patients, cross-sectionally and longitudinally. Methods Cross-sectionally, 95 TS patients were divided into three groups based on their age at initiation of ERT: A (12–14 years, 11 patients), B (15–17 years, 47 patients), and C (over 18 years, 37 patients). To assess bone quality, trabecular bone score (TBS) was used. The effects of age at initiation and duration of ERT on TBS were examined using multiple regression analysis. In the longitudinal study, 48 patients who underwent dual-energy X-ray absorptiometry multiple times were divided into three groups: D (12–14 years, 8 patients), E (15–17 years, 18 patients), and F (over 18 years, 22 patients). Each group was analyzed for the rate of change in TBS per year. Results Cross-sectionally, the TBS showed significant differences among the three groups (TBS A, 1.302; B, 1.299; C, 1.245) (p = 0.013); group C was significantly lower than B (p = 0.014); bone quality was degraded. Multiple regression analysis revealed that age at ERT initiation significantly affected the increase in TBS (p = 0.002). Longitudinally, the rate of change of TBS was not significantly different in the three groups (p = 0.73). Conclusion Early initiation of ERT may have positive effects on bone quality in TS. Large prospective studies will be needed.


  • Open Access

    Eldecalcitol increases bone mass in patients with Turner syndrome who have insufficient bone mass acquisition after estrogen replacement therapy

    by Taku Tsuburai, Tomomi Nakamura, Hiromi Yoshikata, Etsuko Miyagi, Hideya Sakakibara

    Most patients with Turner syndrome (TS) exhibit amenorrhea due to premature ovarian failure. Therefore, estrogen replacement therapy (ERT) is required; however, even after undergoing ERT, it is not rare for bone mass acquisition to be insufficient. This study was conducted in two stages, involving a cross-sectional and a prospective interventional study. We recruited 52 TS patients undergoing ERT due to amenorrhea (categorized into low (LB group; n = 23), and normal (NB group; n = 29) bone mass groups) and 7 TS patients who maintained ovarian function (spontaneous menstrual cycle group (MC group)) as controls. We compared bone associated markers between the three groups (LB, NB, and MC). Furthermore, the LB group had concomitant treatment with eldecalcitol (ELD) and ERT for 12 months. The bone mineral density (BMD) of the lumber spine (L2-4) and the bone metabolism markers were then compared before and after the treatment. The bone metabolism markers were significantly higher in the LB group than the NB and MC groups. Furthermore, with the concomitant use of ELD and ERT in the LB group, BMD increased significantly (pre-treatment 0.710 ± 0.056 g/cm2 vs. 0.736 ± 0.062 g/cm2 after 12 months; p < 0.001). TS patients with insufficient bone mass acquisition even after ERT were characterized by a higher turnover in bone metabolism. Therefore, the concomitant use of ELD was considered an effective adjuvant therapy for increasing bone mass.


  • Open Access

    Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study

    by Akifumi Ijuin, Hiromi Yoshikata, Ryoko Asano, Taku Tsuburai, Ritsuko Kikuchi, Hideya Sakakibara


  • Open Access

    Transition of Women with Turner Syndrome from Pediatrics to Adult Health Care: Current Situation and Associated Problems

    by Hideya Sakakibara

    Turner syndrome (TS), a chronic childhood disease, requires growth hormone (GH) treatment for short stature in pediatrics and sex hormone replacement therapy (HRT) in the adult health-care setting with transition during adolescence managed by gynecologists or endocrinologists (1). However, many women with TS are reported to be receiving inadequate health care. Only 24 of 39 (63%) TS patients received regular follow-up in an Australian study (2), and 13 of 102 were lost to follow-up in a Belgian study (3). Thus, the current management of transition of TS patients seems to be inadequate. This is because there are limited numbers of gynecologists or endocrinologists who are familiar with adult TS, and a reliable management plan for TS during transition has not yet been fully established. Turner syndrome women with complete or partial deletion of an X chromosome will develop various complications in each life stage (Figure 1). In addition to short stature, cardiovascular disease, kidney disease, and otitis media are often observed in childhood. GH therapy is performed for short stature in childhood and in adolescence they require HRT to acquire secondary sexual characteristics due to ovarian dysfunction. In adulthood, ovarian dysfunction causes infertility and osteoporosis. Endocrine/metabolic abnormalities, such as thyroid dysfunction, impaired glucose tolerance, hypertension, dyslipidemia, and gonadal tumors due to Y chromosome components are also observed. Therefore, all health problems that present during childhood should be followed-up in later life. Figure 1. Complications in women with TS. In our department, health management of TS adults is performed in Women’s Health Care Clinic by gynecologists who are familiar with the above conditions. Women’s health problems, due to the female-specific endocrine environment, change throughout every life stage (4). The salient points for TS health management are (1) commencement of HRT for ovarian dysfunction, (2) management of childhood onset complications, and (3) screening for complications that may develop in adulthood. At every visit, blood pressure and body weight were measured. Blood liver function, renal function, glucose tolerance, lipids, thyroid function, and urine analysis were measured once a year. Bone mineral density, ultrasound measurement of uterine size, and aortic MRI were performed at first visit. When a complication developed in a patient, she was referred to the relevant health-care professionals. Gawlik and Malecka-Tendera (5) have also demonstrated that all medical problems that present during childhood should be followed in adult life, with particular importance assigned to screening for hypertension, diabetes mellitus, dyslipidaemia, and osteoporosis. It has been recommended in the guidelines (1) that transition care should be continued up to 18 years of age before transfer to adult health care, in which a gynecologist who is familiar with the unique problems of TS adults, such as ovarian dysfunction and infertility, is involved. HRT is recommended to start at 12–15 years old. However, in our department, the age at completion of GH therapy, in patients referred from pediatrics, was 17.7 ± 2.1 years old, the age of commencement of HRT was 17.9 ± 2.2 years of age, and the age at the time of transition was 23.4 ± 4.1 years of age. On the other hand, in survivors of childhood cancer, the starting age for HRT was 14.1 ± 1.2 years of age and the age of transition was 14.5 ± 1.9 years old (6). Our data shows that transition was not fully completed, although HRT was initiated and GH therapy had been completed. The transition from pediatrics was later than that recommended because of a delay in the end of GH therapy and initiation of HRT. Since there is a lifetime increased risk of complications in TS women, the needs for a systematic and holistic approach in the provision of health care and the establishment of an optimal model of transition to adult health care in TS women are essential (7). A pediatric gynecology clinic was opened in Kanagawa Children’s Medical Center for the management of HRT in childhood and to ensure a smooth transition to our department from the time of GH therapy completion to starting HRT. We conclude that in the future, gynecologists should be more involved in coordinating the initiation of HRT in order to create a smoother transition from pediatrics to adult health care for the management of women with TS. The author confirms being the sole contributor of this work and approved it for publication. The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 1. Bondy CA; Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab (2007) 92:10–25. doi:10.1210/jc.2006-1374 PubMed Abstract | CrossRef Full Text | Google Scholar 2. Pedreira CC, Hameed R, Kanumakala S, Zacharin M. Health-care problems of Turner syndrome in the adult woman: a cross sectional study of a Victorian cohort and a case for transition. Intern Med J (2006) 36:54–7. doi:10.1111/j.1445-5994.2005.00990.x CrossRef Full Text | Google Scholar 3. Verlinde F, Massa G, Lagrou K, Froidecoeur C, Bourguignon JP, Craen M, et al. Health and psychosocial status of patients with Turner syndrome after transition to adulthood: the Belgian experience. Horm Res (2004) 62:161–7. doi:10.1159/000080099 CrossRef Full Text | Google Scholar 4. Sakakibara H, Yoshida H, Takei M, Katsuhata Y, Koyama M, Nagata T, et al. Health management of adults with Turner syndrome: an attempt at multidisciplinary medical care by gynecologists in cooperation with specialists from other fields. J Obstet Gynaecol Res (2011) 37:836–42....


  • Case of early postoperative adhesion in a patient with molimina due to transverse vaginal septum concomitant with imperforate hymen

    by Makiko Koyama‐Sato, Osamu Hashida, Tomomi Nakamura, Fumiki Hirahara, Hideya Sakakibara

    Transverse vaginal septum is a residual vaginal plate composed of the Müllerian duct and urogenital sinus. Imperforate hymen results from failure of perforation of the membrane between the urogenital sinus and vaginal cavity. We report a rare case of concurrence of these two conditions. A 16-year-old girl had been treated with puncture several times for hematometra and hematocolpos from 13 years of age because of monthly occurrence of lower abdominal pain without menstrual bleeding and was referred to our hospital. Magnetic resonance imaging demonstrated hematometra, hematocolpos and expansion of the vaginal fornix. The imperforate hymen was incised and a slight adhesion at the lower vaginal cavity was detached. After that, a complete transverse vaginal septum, which was 5 mm thick, was identified. It was excised after ultrasonography-guided puncture. Although two cycles of menstrual bleeding took place, molimina recurred. Re-operation was performed 6 months after the first operation, and recurrence of adhesion in the lower vaginal cavity was identified. A silicon dilator was inserted, but she could not use it at home and instead used a tampon. Cyclic menstrual bleeding is observed 4 months after the second operation.


  • Steroid cell tumour, not otherwise specified: Rare case with primary amenorrhoea in a 16-year-old

    by T. Yokozawa, R. Asano, T. Nakamura, M. Furuya, Y. Nagashima, M. Koyama-Sato, Y. Kanda, F. Hirahara, H. Sakakibara


  • Open Access

    A case of empty follicle syndrome who conceived after aspiration of an endometrial cyst

    by Rieko Tanaka, Mariko Murase, Yoshino Aizawa, Miwa Segino, Yumi Ishidera, Masakazu Kitagawa, Kayo Katayama, Kunitomo Takashima, Yasushi Yumura, Hiroshi Yoshida, et al.

    Empty follicle syndrome (EFS) has been defined as a condition where no oocytes can be retrieved for in vitro fertilization (IVF) even though ultrasound findings and estradiol (E2) levels suggest the presence of potential follicles. The EFS is a rare condition with an incidence of 0.5–7 % of women undergoing IVF treatments. Although there are many hypotheses as to the cause of EFS, including advanced ovarian age, drug‐related problems, and dysfunctional folliculogenesis, its cause remains unknown. A 37‐year‐old woman with endometriosis and a 5‐year history of primary infertility underwent IVF treatment for 4 cycles. No oocytes were retrieved in 2 cycles and no fertilized eggs were obtained in the other 2 cycles. We assumed that endometriosis adversely affected folliculogenesis and fertilization. Aspiration of an endometrial cyst in the right ovary and subsequent administration of oral contraceptives resulted in successful folliculogenesis and fertilization. Thereafter, she conceived and delivered a 2,662 g female infant at 38 weeks of gestation. Here, we report a case of EFS who conceived in the 5th IVF cycle after aspiration of an endometrial cyst. We assumed that endometriosis might have been involved in the dysfunction of folliculogenesis and EFS.


  • Open Access

    Continuous Stimulation of Gonadotropin-Releasing Hormone (GnRH) Receptors by GnRH Agonist Decreases Pituitary GnRH Receptor Messenger Ribonucleic Acid Concentration in Immature Female Rats.

    by Hideya Sakakibara, Michiyoshi Taga, Mario Ikeda, Keiko Kurogi, Hiroshi Minaguchi

    Although it is well recognized that continuous administration of gonadotropin-releasing hormone agonist (GnRHa) induces pituitary desensitization, the precise molecular mechanism of this phenomenon is still unclear. To test the hypothesis that pituitary gonadotroph desensitization is mediated by a change in GnRH receptor (GnRH-R) gene expression, the GnRH-R mRNA concentration was analyzed in immature female rats during GnRHa treatment. Northern blot hybridization was used to determine the GnRH-R mRNA concentration several times after an injection of TAP-144-SR, a slow releasing GnRHa. The GnRH-R mRNA readings were 92.7 +/- 9.5%, 49.9 +/- 5.0%, 35.7 +/- 2.3% and 73.8 +/- 5.7% (Mean +/- SD) compared to each control value at 1, 2, 4 and 8 weeks, respectively, after a single injection of 0.94 mg TAP-144 SR. These changes in GnRH-R mRNA coincided with the changes in gonadotropin secretion and LH-beta mRNA in response to GnRH in the results of our previous report. The present results indicate that the reduction of the number of pituitary GnRH-R sites induced by continuous stimulation with GnRHa is regulated at a transcriptional level.